American Journal of Preventive Cardiology (Mar 2024)

Trends in prevalence, risk factor control and medications in atherosclerotic cardiovascular disease among US Adults, 1999–2018

  • Xiaowen Zhang,
  • Zheng Chen,
  • Aijuan Fang,
  • Lina Kang,
  • Wei Xu,
  • Biao Xu,
  • Jianzhou Chen,
  • Xinlin Zhang

Journal volume & issue
Vol. 17
p. 100634

Abstract

Read online

Objectives: Trends in prevalence and treatments of atherosclerotic cardiovascular disease (ASCVD) remains to be documented, with frequent update of relevant guidelines. We aimed to characterize trends in prevalence of ASCVD, and risk factor control and medications among ASCVD adults. Methods: We conducted a cross-sectional analysis of data from 55,081 adults in the National Health and Nutrition Examination Surveys (NHANES) 1999–2018. Results: The age-standardized prevalence of ASCVD did not change significantly from 1999–2002 (7.9 %, 95 % CI 7.1 %–8.7 %) to 2015–2018 (7.5 %, CI 6.8 %–8.3 %) (P for trend =0.18), representing an estimated 19.9 million individuals with ASCVD in 2015–2018. The prevalence of premature ASCVD was 2.0 % (CI, 1.6 %–2.5 %). Over 60.0 % of ASCVD participants were at very-high risk. From 1999–2002 to 2015–2018, the percentage with lipid control (non-high-density lipoprotein cholesterol <100 mg/dL) increased from 7.0 % (CI, 3.5 %–12.3 %) to 26.4 % (CI, 16.2 %–38.9 %). The percentage with blood-pressure control (<130/80 mmHg) increased from 51.2 % (CI, 41.0 %–61.3 %) in 1999–2002 to 57.2 % (CI, 48.4 %–65.6 %) in 2011–2014, but then declined to 52.8 % (CI, 44.4 %–81.3 %) in 2015–2018. The percentage with glycemic control (HbA1c <7.0 %) decreased from 95.0 % (CI, 90.2 %–97.9 %) to 84.0 % (CI, 75.9 %–90.3 %). The percentage who achieved all 3 targets was 18.6 % (CI, 8.2 %–33.8 %) in 2015–2018. The percentage of ASCVD participants who were taking statins increased from 1999–2002 to 2011–2014, but then leveled off. Approximately 60 % of individuals with ASCVD and less than 40 % of those with premature ASCVD were taking statins in 2015–2018. The utilization of blood-pressure-lowering drugs remained largely constant over time, whereas the use of glucose-lowering drugs increased. Conclusions: Based on NHANES data from US adults, the estimated prevalence of ASCVD remained relatively stable between 1999 and 2018. Substantial undertreatment with stains was found in individuals with ASCVD, and the percentage achieving optimal lipid control was low.

Keywords